MuffinsDaddy
2021-12-22
O
Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691666770,"tweetId":"691666770","gmtCreate":1640185026998,"gmtModify":1640185027378,"author":{"id":3584049778248855,"idStr":"3584049778248855","authorId":3584049778248855,"authorIdStr":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":38,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>O</p></body></html>","htmlText":"<html><head></head><body><p>O</p></body></html>","text":"O","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691666770","repostId":1163953446,"repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohunote.com/m/news/1163953446?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos 继续下滑，盘前下跌 87.4%，此前昨天宣布其后期研究 KRYPTOS 和 ENIGMA 2 未能达到统计显著性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究符合其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至大盘。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但在两项研究中未能达到患者报告症状的共同主要终点，这引发了人们对这些组织学改善是否可以转化为临床改善的疑问。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于 lirentelimab 的表现不如安慰剂，显然存在一个问题，即为什么 II 期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen 分析师 Joseph Thome 还将 Allakos 的建议从跑赢大盘下调至市场表现，但目标价 (PT) 尚待管道明朗。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink 分析师 Thomas Smith 将该股评级从跑赢大盘下调至大盘，PT 为 17 美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>巴克莱银行分析师 Carter Gould 将该公司对 Allakos 的市盈率从 36 美元下调至 8 美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败。他认为这是lirentelimab的“终局”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos 令人失望的数据增加了嗜酸性粒细胞性胃肠道疾病 (EGIDs) 的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.</p><p><blockquote>Jefferies 分析师 Maury Raycroft 将 Allakos 的评级从“买入”下调至“持有”。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital 分析师 Samuel Slutsky 将该股评级从跑赢大盘下调至大盘。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 22:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos 继续下滑，盘前下跌 87.4%，此前昨天宣布其后期研究 KRYPTOS 和 ENIGMA 2 未能达到统计显著性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究符合其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至大盘。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但在两项研究中未能达到患者报告症状的共同主要终点，这引发了人们对这些组织学改善是否可以转化为临床改善的疑问。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于 lirentelimab 的表现不如安慰剂，显然存在一个问题，即为什么 II 期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen 分析师 Joseph Thome 还将 Allakos 的建议从跑赢大盘下调至市场表现，但目标价 (PT) 尚待管道明朗。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink 分析师 Thomas Smith 将该股评级从跑赢大盘下调至大盘，PT 为 17 美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>巴克莱银行分析师 Carter Gould 将该公司对 Allakos 的市盈率从 36 美元下调至 8 美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败。他认为这是lirentelimab的“终局”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos 令人失望的数据增加了嗜酸性粒细胞性胃肠道疾病 (EGIDs) 的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.</p><p><blockquote>Jefferies 分析师 Maury Raycroft 将 Allakos 的评级从“买入”下调至“持有”。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital 分析师 Samuel Slutsky 将该股评级从跑赢大盘下调至大盘。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1,"symbols_score_info":{"ALLK":0.9}},"isVote":1,"tweetType":1,"viewCount":3420,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691666770"}
精彩评论